Enhancing postmarketing surveillance: Continuing challenges

British Journal of Clinical Pharmacology

Volumn 80, Issue 4, 2015, Pages 615-617

  French, Dustin D ^a,d   Margo, Curtis E ^b   Campbell, Robert R ^c,e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c VISN 8 Patient Safety Center of Inquiry   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

^e NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR;

CLINICAL TRIAL (TOPIC); DRUG EXPOSURE; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; HEALTH CARE SYSTEM; HUMAN; NOTE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; DRUG SURVEILLANCE PROGRAM;

ADVERSE DRUG REACTION REPORTING SYSTEMS; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 84942552031     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12658     Document Type: Note

References (12)

1. Zeitoun J-D, Lefèvre JH, Downing NS, Bergeron H, Ross JS,. Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study. Br J Clin Pharmacol 2015 2015; 80: 716-26.
2. Frank C, Himmelstein DU, Woolhandler S, Bor DH, Wolfe SM, Heymann O, Zallman L, Lasser KE,. Era of faster FDA drug approval has also seen increased black-box warning and market withdrawals. Health Aff 2015; 33: 1353-9.
3. Pomeranz HD, Bhavsar AR,. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (Viagra): a report of seven new cases. J Neuroophthalmol 2005; 25: 9-13.
4. Barbehenn E, Lurie P, Wolfe SM, Pomeranz HD,. Petition to require a black box warning for erectile dysfunction drugs sildenafil (Viagra), tadalafil (Cialis) and vardenafil (Levitra), 20 October 2005. Available at http://www.citizen.org / (last accessed 24 March 2015).
5. Margo CE, French DD,. Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors. Am J Ophthlamol 2007; 143: 538-9.
6. Nathoo NA, Etminan M, Mikelberg FS,. Association between phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy. J Neuro-Ophthalmol 2015; 35: 12-5.
7. French DD, Margo CE,. Post-marketing surveillance of ischaemic optic neuropathy in male veterans co-prescribed phosphodiesterase-5 inhibitors with organic nitrates or alpha-blockers. Drug Saf 2008; 31: 241-7.
8. Campbell UB, Walker AM, Gaffney M, Petronis KR, Creanga D, Quinn S, Klein BE, Laties AM, Lewis M, Sharlip ID, Kolitsopoulos F, Klee BJ, Mo J, Reynolds RF,. Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors. J Sex Med 2015; 12: 139-51.
9. Campbell RR, Spehar AM, French DD,. Proactive postmarketing surveillance: overview and lessons learned from medication safety research in the veterans health administration. In: Advances in Patient Safety: New Directions and Alternative Approaches (Vol. 1: Assessment), eds, Henriksen K, Battles JB, Keyes MA, Grady ML, Rockville, MD: Agency for Healthcare Research and Quality, 2008. Available at: http://www.ahrq.gov/professionals/quality-patient-safety/patient-safety-resources/resources/advances-in-patient-safety-2/vol1/Advances-Campbell-R-106.pdf (last accessed 1 April 2015).
10. French DD,. Impact of health information exchange on VA patient costs. Academy Health National Meeting, June 2014. San Diego, CA. Available at: http://www.academyhealth.org/files/2014/monday/french.pdf (last accessed 1 April 2015).
11. FDA Guidance. ' Off-label' and investigational use of marketed drugs, biologics, and medical devices-information sheet-guidance for institutional review boards and clinical investigators, 2014. Available at: http://www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm (last accessed 30 March 2015).
12. Rodwin M,. Rooting out institutional corruption to manage inappropriate off-label drug use. J Law Med Ethics 2013; 41: 654-64.